Truist lowered the firm’s price target on Molina Healthcare (MOH) to $175 from $210 and keeps a Hold rating on the shares. The company posted challenging Q3 results where ongoing medical cost pressures resulted in an adjusted EPS miss while FY25 guidance was cut, with initial FY26 comments pointing to earnings similar to FY25 levels, the analyst tells investors in a research note. Medicaid commentary was constructive however relative to the difficult environment, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MOH:
- Coinbase, eBay upgraded: Wall Street’s top analyst calls
- Molina Healthcare price target lowered to $158 from $204 at Morgan Stanley
- Molina Healthcare price target lowered to $170 from $180 at UBS
- Molina Healthcare price target lowered to $180 from $210 at Cantor Fitzgerald
- Molina Healthcare price target lowered to $167 from $207 at Goldman Sachs